JWH-073 Stats & Data
CCCCn1cc(C(=O)c2cccc3ccccc23)c2ccccc12VCHHHSMPMLNVGS-UHFFFAOYSA-NPharmacology
DrugBankMechanism of Action
/Synthetic cannabinoid/ agonistic activity on the CB1 receptor is responsible for elevating mood and inducing a feeling of well-being. Some /synthetic cannabinoid/ users have reported effects similar to or even stronger than those obtained by smoking cannabis, such as physical relaxation, changes in perception, and mild euphoria.
Metabolism
... The lack or low content of /JWH-018 and JWH-073/ in urine requires detailed identification of their metabolites, which are excreted with urine and are present in blood. Using gas and liquid chromatography-mass spectrometry, /investigators/ identified a series of metabolites in urine samples from humans and rats that were products of the following reactions: (a) mono- and dihydroxylation of the parent compounds with hydroxyl groups located at aromatic and aliphatic residues, (b) carboxylation
Receptor Profile
Receptor Actions
History & Culture
JWH-073 derives its name from John W. Huffman, the American organic chemist whose laboratory developed this and numerous other synthetic cannabinoid compounds as part of cannabinoid receptor research. The "JWH" prefix identifies compounds originating from Huffman's work. The compound entered the recreational drug market as a component of herbal smoking blends sold under the "Spice" brand name during the late 2000s. It was reportedly among the first variations from JWH-018 to appear in the original Spice product line. In April 2009, researchers at the University of Freiburg identified JWH-073 in a product deceptively marketed as "Forest Humus" fertilizer, alongside another synthetic cannabinoid. Following Germany's prohibition of JWH-018, testing of seized Spice products in July 2009 revealed that manufacturers had reformulated their blends to contain the then-unscheduled JWH-073 as a substitute compound. The authentic Spice brand eventually disappeared from the market before the proliferation of more potent synthetic cannabinoids under numerous other product names and labels. However, its cultural impact endured, with the term "Spice" becoming widely adopted as a generic descriptor for synthetic cannabinoid products regardless of their actual composition—a misappropriation of the original brand name that persists in colloquial usage.
Tolerance & Pharmacokinetics
drugs.wikiTolerance Decay
Experience Report Analysis
ErowidDemographics
Gender Distribution
Age Distribution
Reports Over Time
Effect Analysis
ErowidEffects aggregated from 34 experience reports (34 Erowid)
Effect Sentiment Distribution
Confidence Distribution
Positive Effects 10
Adverse Effects 9
Form / Preparation
Most common forms and preparations reported
Legal Status
| Country | Status | Notes |
|---|---|---|
| Australia | Schedule 9 | Prohibited substance under the Poisons Standard since July 8, 2011. Schedule 9 classification restricts manufacture, possession, sale, and use except when required for approved medical or scientific research, or for analytical, teaching, or training purposes with authorization from Commonwealth and/or State or Territory Health Authorities. |
| Germany | Anlage II BtMG | Classified under the Betäubungsmittelgesetz (Narcotics Act). Was initially unregulated and appeared as a substitute compound in Spice products following Germany's prohibition of JWH-018 in 2009, before being subsequently controlled. |
| New Zealand | Banned | Sale prohibited as of May 8, 2014. |
| Turkey | Banned | Sale prohibited as of January 7, 2011. |
| United States | Schedule I | Temporarily designated as Schedule I on March 1, 2011 through 76 FR 11075, then permanently classified under Schedule I on July 9, 2012 via Section 1152 of the Food and Drug Administration Safety and Innovation Act. |
References
Data Sources
Cited References
- Aung et al. 2000: Influence of N-1 alkyl chain length on CB receptor binding
- Bluelight: JWH-073 Discussion Threads
- Drugs-Forum: Cannabinoid Dose and Duration Chart
- Erowid: JWH-073 Experience Vault
- Every-Palmer 2011: Synthetic cannabinoid JWH-018 and psychosis
- Frontiers in Neuroscience: JWH-073 and JWH-210 Behavioral Profile
- PMC: JWH-073 Electrophysiological Effects in Mice
- PsychonautWiki: JWH-073
- Rajasekaran et al. 2013: Human metabolites of JWH-018 and JWH-073
- ScienceDirect Topics: JWH-073 Overview
- WHO Expert Committee on Drug Dependence: JWH-073